A pyrrolopyrimidine-based TYRO3 inhibitor for primary effusion lymphoma

DISEASE CATEGORY: Cancer

INDICATION: Non-Hodgkin lymphoma (NHL)

A UNC Chapel Hill team identified a pyrrolopyrimidine-based inhibitor of TYRO3 that could

Read the full 181 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE